Zeng Yiping, Opeskin Kenneth, Baldwin Megan E, Horvath Lisa G, Achen Marc G, Stacker Steven A, Sutherland Robert L, Williams Elizabeth D
Bernard O'Brien Institute of Microsurgery, Melbourne, Australia.
Clin Cancer Res. 2004 Aug 1;10(15):5137-44. doi: 10.1158/1078-0432.CCR-03-0434.
The molecular mechanisms underlying lymph node metastasis are poorly understood, despite the well-established clinical importance of lymph node status in many human cancers. Recently, vascular endothelial growth factor (VEGF)-C and VEGF-D have been implicated in the regulation of tumor lymphangiogenesis and enhancement of lymphatic invasion via activation of VEGF receptor-3. The purpose of this study was to determine the expression pattern of the VEGF-C/VEGF-D/VEGF receptor-3 axis in prostate cancer and its relationship with lymph node metastasis.
The expression pattern of VEGF-C, VEGF-D, and VEGF receptor-3 in localized prostate cancer specimens (n = 37) was determined using immunohistochemistry.
Widespread, heterogeneous staining for VEGF-C and VEGF-D was observed in all cancer specimens. Intensity of VEGF-C staining was lower in benign prostate epithelium than in adjacent carcinoma, whereas no difference between benign epithelium and carcinoma was observed for VEGF-D staining. VEGF receptor-3 immunostaining was detected in endothelial cells of lymphatic vessels in 18 of 37 tissue samples. The presence of VEGF receptor-3-positive vessels was associated with lymph node metastasis (P = 0.0002), Gleason grade (P < 0.0001), extracapsular extension (P = 0.0382), and surgical margin status (P = 0.0069). In addition, VEGF receptor-3 staining highlighted lymphatic invasion by VEGF-C-positive/VEGF-D-positive carcinoma cells.
Together, these results suggest that paracrine activation of lymphatic endothelial cell VEGF receptor-3 by VEGF-C and/or VEGF-D may be involved in lymphatic metastasis. Thus the VEGF-C/VEGF-D/VEGF receptor-3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer.
尽管淋巴结状态在许多人类癌症中具有已确立的临床重要性,但对淋巴结转移背后的分子机制了解甚少。最近,血管内皮生长因子(VEGF)-C和VEGF-D被认为参与肿瘤淋巴管生成的调节以及通过激活VEGF受体-3增强淋巴侵袭。本研究的目的是确定VEGF-C/VEGF-D/VEGF受体-3轴在前列腺癌中的表达模式及其与淋巴结转移的关系。
使用免疫组织化学法确定37例局限性前列腺癌标本中VEGF-C、VEGF-D和VEGF受体-3的表达模式。
在所有癌症标本中均观察到VEGF-C和VEGF-D广泛、异质性染色。良性前列腺上皮中VEGF-C染色强度低于相邻癌组织,而VEGF-D染色在良性上皮和癌组织之间未观察到差异。在37个组织样本中的18个样本中,在淋巴管内皮细胞中检测到VEGF受体-3免疫染色。VEGF受体-3阳性血管的存在与淋巴结转移(P = 0.0002)、Gleason分级(P < 0.0001)、包膜外侵犯(P = 0.0382)和手术切缘状态(P = 0.0069)相关。此外,VEGF受体-3染色突出显示了VEGF-C阳性/VEGF-D阳性癌细胞的淋巴侵袭。
这些结果共同表明,VEGF-C和/或VEGF-D对淋巴管内皮细胞VEGF受体-3的旁分泌激活可能参与淋巴转移。因此,VEGF-C/VEGF-D/VEGF受体-3信号通路可能为前列腺癌的抗淋巴管生成治疗提供靶点。